JOHNSON & JOHNSON | 2013 | FY | 3

Segments of Business and Geographic Areas
 
 
Sales to Customers
(Dollars in Millions)
 
2013
 
2012
 
2011
Consumer —
 
 
 
 
 
 
United States
 
$
5,162

 
5,046

 
5,151

International
 
9,535

 
9,401

 
9,732

Total
 
14,697

 
14,447

 
14,883

Pharmaceutical —
 
 
 
 
 
 
United States
 
13,948

 
12,421

 
12,386

International
 
14,177

 
12,930

 
11,982

Total
 
28,125

 
25,351

 
24,368

Medical Devices and Diagnostics —
 
 
 
 
 
 
United States
 
12,800

 
12,363

 
11,371

International
 
15,690

 
15,063

 
14,408

Total
 
28,490

 
27,426

 
25,779

Worldwide total
 
$
71,312

 
67,224

 
65,030


 
 
Pre-Tax Profit
 
Identifiable Assets
(Dollars in Millions)
 
2013 (3)
 
2012 (4)
 
2011 (5)
 
2013
 
2012
 
2011
Consumer
 
$
1,973

 
1,693

 
2,096

 
$
23,711

 
24,131

 
24,210

Pharmaceutical
 
9,178

 
6,075

 
6,406

 
23,783

 
23,219

 
23,747

Medical Devices and Diagnostics
 
5,261

 
7,187

 
5,263

 
44,585

 
42,926

 
23,609

Total
 
16,412

 
14,955

 
13,765

 
92,079

 
90,276

 
71,566

Less: Expense not allocated to segments (1)
 
941

 
1,180

 
1,404

 
 
 
 
 
 
General corporate (2)
 
 
 
 
 
 
 
40,604

 
31,071

 
42,078

Worldwide total
 
$
15,471

 
13,775

 
12,361

 
$
132,683

 
121,347

 
113,644


 
 
Additions to Property,
Plant & Equipment
 
Depreciation and
Amortization
(Dollars in Millions)
 
2013
 
2012
 
2011
 
2013
 
2012
 
2011
Consumer
 
$
533

 
468

 
670

 
$
539

 
575

 
631

Pharmaceutical
 
856

 
737

 
729

 
1,075

 
1,010

 
958

Medical Devices and Diagnostics
 
1,724

 
1,230

 
1,095

 
2,224

 
1,857

 
1,331

Segments total
 
3,113

 
2,435

 
2,494

 
3,838

 
3,442

 
2,920

General corporate
 
482

 
499

 
399

 
266

 
224

 
238

Worldwide total
 
$
3,595

 
2,934

 
2,893

 
$
4,104

 
3,666

 
3,158



 
 
Sales to Customers
 
Long-Lived Assets (6)
(Dollars in Millions)
 
2013
 
2012
 
2011
 
2013
 
2012
 
2011
United States
 
$
31,910

 
29,830

 
28,908

 
$
35,880

 
35,115

 
23,529

Europe
 
18,599

 
16,945

 
17,129

 
24,868

 
25,261

 
19,056

Western Hemisphere excluding U.S. 
 
7,421

 
7,207

 
6,418

 
3,281

 
3,636

 
3,517

Asia-Pacific, Africa
 
13,382

 
13,242

 
12,575

 
2,434

 
2,362

 
2,163

Segments total
 
71,312

 
67,224

 
65,030

 
66,463

 
66,374

 
48,265

General corporate
 
 
 
 
 
 
 
992

 
899

 
750

Other non long-lived assets
 
 
 
 
 
 
 
65,228

 
54,074

 
64,629

Worldwide total
 
$
71,312

 
67,224

 
65,030

 
$
132,683

 
121,347

 
113,644

­
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2013, 2012 and 2011, the Company did not have a customer that represented 10% of total revenues.
(1) 
Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.
(2) 
General corporate includes cash and marketable securities.
(3) 
Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Diagnostics and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
(4) 
Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
(5) 
Includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program.
(6) 
Long-lived assets include property, plant and equipment, net for 2013, 2012 and 2011 of $16,710, $16,097 and $14,739, respectively, and intangible assets and goodwill, net for 2013, 2012 and 2011 of $50,745, $51,176 and $34,276, respectively.

us-gaap:SegmentReportingDisclosureTextBlock